Company profile for Scenic Biotech

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Scenic Biotech is focused on identifying genetic modifiers, a completely new class of disease targets, for drug intervention. Also known as disease suppressors, genetic modifiers are genes that act to suppress or completely block the effect of a disease-causing mutated gene. As a pioneer in the field, Scenic Biotech is building the largest proprietary data warehouse of genetic modifiers and has already identified a number o...
Scenic Biotech is focused on identifying genetic modifiers, a completely new class of disease targets, for drug intervention. Also known as disease suppressors, genetic modifiers are genes that act to suppress or completely block the effect of a disease-causing mutated gene. As a pioneer in the field, Scenic Biotech is building the largest proprietary data warehouse of genetic modifiers and has already identified a number of novel genetic modifiers for over a dozen inherited diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Netherlands
Address
Address
Science Park 106 1098 XG Amsterdam The Netherlands
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/09/09/3146655/0/en/Scenic-Biotech-Appoints-Dr-Roland-W-B%C3%BCrli-as-CSO-to-Advance-Pipeline-of-Modifier-Therapies-in-Neuro-and-Metabolic-Diseases.html

GLOBENEWSWIRE
09 Sep 2025

https://www.globenewswire.com/news-release/2025/09/03/3143863/0/en/Scenic-Biotech-Publishes-Novel-Drug-Target-for-Mitochondrial-and-Cardiac-Disease-in-Nature.html

GLOBENEWSWIRE
03 Sep 2025

https://www.globenewswire.com/news-release/2025/08/26/3139048/0/en/Scenic-Enters-License-and-Research-Agreement-with-Alnylam.html

GLOBENEWSWIRE
26 Aug 2025

https://www.globenewswire.com/news-release/2025/05/07/3076353/0/en/Scenic-Biotech-Announces-Nature-Publication-on-the-Discovery-of-Drug-Target-PLA2G15-a-Modifier-in-Lysosomal-Disease.html

GLOBENEWSWIRE
07 May 2025

https://www.businesswire.com/news/home/20240711671692/en

BUSINESSWIRE
11 Jul 2024

https://www.businesswire.com/news/molecularlab/20240430653910/en/Scenic-Biotech-Enters-into-Research-Collaboration-with-Bristol-Myers-Squibb

BUSINESSWIRE
30 Apr 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty